BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 16116470)

  • 1. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
    Oppenheim DE; Roberts SJ; Clarke SL; Filler R; Lewis JM; Tigelaar RE; Girardi M; Hayday AC
    Nat Immunol; 2005 Sep; 6(9):928-37. PubMed ID: 16116470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon.
    Nausch N; Florin L; Hartenstein B; Angel P; Schorpp-Kistner M; Cerwenka A
    J Immunol; 2006 Jan; 176(1):7-11. PubMed ID: 16365389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice.
    Lin Z; Wang C; Xia H; Liu W; Xiao W; Qian L; Jia X; Ding Y; Ji M; Gong W
    Immunology; 2014 Mar; 141(3):401-15. PubMed ID: 24708417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
    Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
    Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
    Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
    J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
    Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
    J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
    Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
    Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.
    Lodoen M; Ogasawara K; Hamerman JA; Arase H; Houchins JP; Mocarski ES; Lanier LL
    J Exp Med; 2003 May; 197(10):1245-53. PubMed ID: 12756263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
    Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
    Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.
    Coudert JD; Zimmer J; Tomasello E; Cebecauer M; Colonna M; Vivier E; Held W
    Blood; 2005 Sep; 106(5):1711-7. PubMed ID: 15886320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.
    Ogasawara K; Benjamin J; Takaki R; Phillips JH; Lanier LL
    Nat Immunol; 2005 Sep; 6(9):938-45. PubMed ID: 16086018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of V gamma 9V delta 2 T cells by NKG2D.
    Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
    J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T; Lemoi BA; Sentman CL
    Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of cutaneous malignancy by gammadelta T cells.
    Girardi M; Oppenheim DE; Steele CR; Lewis JM; Glusac E; Filler R; Hobby P; Sutton B; Tigelaar RE; Hayday AC
    Science; 2001 Oct; 294(5542):605-9. PubMed ID: 11567106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An activating immunoreceptor complex formed by NKG2D and DAP10.
    Wu J; Song Y; Bakker AB; Bauer S; Spies T; Lanier LL; Phillips JH
    Science; 1999 Jul; 285(5428):730-2. PubMed ID: 10426994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis.
    Strid J; Roberts SJ; Filler RB; Lewis JM; Kwong BY; Schpero W; Kaplan DH; Hayday AC; Girardi M
    Nat Immunol; 2008 Feb; 9(2):146-54. PubMed ID: 18176566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.